Emerging LDL therapies: Mipomersen - Antisense oligonucleotide therapy in the management of hypercholesterolemia

Journal of Clinical Lipidology

Volumn 7, Issue 3 SUPPL., 2013, Pages S6-

  Toth, Peter P ^a,b  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Antisense oligonucleotide; Apolipoprotein B; Familial hypercholesterolemia; Low density lipoprotein cholesterol; Mipomersen

Indexed keywords

APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN;

ANTISENSE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG BINDING; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GENETIC SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT;

EID: 84877584144     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.02.004     Document Type: Article

References (17)

1. A.C. Goldberg Novel therapies and new targets of treatment for familial hypercholesterolemia J Clin Lipidol 4 2010 350 356
2. Genzyme and Isis announce FDA approval of KYNAMRO™ (mipomersen sodium) injection for the treatment of homozygous familial hypercholesterolemia. Press release, genyzme and Isis Pharmaceuticals. Available at: http://en.sanofi.com/Images/31810-20130129-KYNAMRO-FDA-APPROVAL-en.pdf. Accessed March 27, 2013.
3. P.N. Hopkins, P.P. Toth, C.M. Ballantyne, D.J. Rader National Lipid Association Expert Panel on Familial Hypercholesterolemia Familial hypercholesterolemias: prevalence, genetics, diagnosis, and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 3 Suppl 2011 S9 S17
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
5. S.T. Crooke Antisense Drug Technology: Principles, Strategies, and Applications 2nd ed. 2008 Marcel Dekker, Inc New York 601 639
6. P.P. Toth Antisense therapy and emerging applications for the management of dyslipidemia J Clin Lipidol 5 2011 441 449
7. J.J. Kastelein, M.K. Wedel, and B.F. Baker Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein Circulation 114 2006 1729 1735
8. R. Yu, T.W. Kim, and A. Hong Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100 Drug Metab Dispos 35 2007 460 468
9. M.E. Visser, J.L. Witztum, E.S. Stroes, and J.J. Kastelein Antisense oligonucleotides for the treatment of dyslipidaemia Eur Heart J 33 2012 1451 1458
10. R. Yu, R.S. Geary, and J.D. Flaim Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe Clin Pharmacokinet 48 2009 39 50
11. F.J. Raal, R.D. Santos, and D.J. Blom Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
12. E. Stein, R. Dufour, and C. Gagne A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on-therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease Eur Heart J 31 Suppl 1 2010 Abstract
13. J.C. Tardif, R. Ceska, L.J. Burgess Montreal Heart Institute, Montreal, Canada Apolipoprotein B-synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia [abstract] J Am Coll Cardiol 2011 920 923 E-abstract
14. W.C. Cromwell, G.S. Thomas, I. Boltje, W. Chin, and M. Davidson Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk J Am Coll Cardiol 57 2011 1011 1304 Poster
15. FDA Briefing Document. NDA 203568: mipomersen sodium injection, 200 mg/mL. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM323927.pdf. Accessed March 27, 2013.
16. M.E. Visser, F. Akdim, and D.L. Tribble Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia J Lipid Res 51 2010 1057 1062
17. Santos R, Duell B, East C, et al. Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia not controlled by maximally tolerated lipid lowering therapy. XVI International Symposium on Atherosclerosis (ISA 2012). March 25-29, 2012, Sydney, Australia. Abstract 790.